Nicole L Pratt - JoVE Visualize

Showing results (91-100 of 103) with videos related to

Pageof 11

Sort By:

Clinical Orthopaedics and Related Research|July 7, 2021

Does a Prescription-based Comorbidity Index Correlate with the American Society of Anesthesiologists Physical Status Score and Mortality After Joint Arthroplasty? A Registry StudyMhairi M Kerr, Stephen E Graves, Katherine M Duszynski, et al.

Drug Safety|April 19, 2023

Prevalence and Preventability of Adverse Medicine Events in a Sample of Australian Aged-Care Residents: A Secondary Analysis of Data from the ReMInDAR TrialLisa M Kalisch Ellett, Gerel Dorj, Andre Q Andrade, et al.

Journal of Internal Medicine|June 7, 2023

Cardiovascular risk in rheumatoid arthritis patients treated with targeted synthetic and biological disease-modifying antirheumatic drugs: A multi-centre cohort studyXinning Tong, Chin-Yao Shen, Ha-Lim Jeon, et al.

The Lancet Regional Health. Western Pacific|July 5, 2022

Monoclonal antibodies and Fc-fusion protein biologic medicines: A multinational cross-sectional investigation of accessibility and affordability in Asia Pacific regions between 2010 and 2020Xinning Tong, Xue Li, Nicole L Pratt, et al.

Pharmacoepidemiology and Drug Safety|February 26, 2021

Suitability of databases in the Asia-Pacific for collaborative monitoring of vaccine safetyKatherine M Duszynski, James H Stark, Catherine Cohet, et al.

BMJ Open|April 25, 2020

Reducing medicine-induced deterioration and adverse reactions (ReMInDAR) trial: study protocol for a randomised controlled trial in residential aged-care facilities assessing frailty as the primary outcomeRenly Lim, Luke Bereznicki, Megan Corlis, et al.

Studies in Health Technology and Informatics|August 8, 2025

Predicting Infection Risk in Rheumatoid Arthritis Patients Treated with Biological and Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs: An Application of Machine LearningKuan Peng, Deliang Yang, Jiaqi Wang, et al.

Age and Ageing|April 23, 2022

Effect of an ongoing pharmacist service to reduce medicine-induced deterioration and adverse reactions in aged-care facilities (nursing homes): a multicentre, randomised controlled trial (the ReMInDAR trial)Elizabeth E Roughead, Nicole L Pratt, Gaynor Parfitt, et al.

Drug Safety|July 29, 2015

Variation in Association Between Thiazolidinediones and Heart Failure Across Ethnic Groups: Retrospective analysis of Large Healthcare Claims Databases in Six CountriesElizabeth E Roughead, Esther W Chan, Nam-Kyong Choi, et al.

Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|March 23, 2023

Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series AnalysisKuan Peng, Joseph E Blais, Nicole L Pratt, et al.

Pageof 11

Showing results (91-100 of 103) with videos related to

Sort By:

Pageof 11

Clinical Orthopaedics and Related Research|July 7, 2021

Does a Prescription-based Comorbidity Index Correlate with the American Society of Anesthesiologists Physical Status Score and Mortality After Joint Arthroplasty? A Registry StudyMhairi M Kerr, Stephen E Graves, Katherine M Duszynski, et al.

Drug Safety|April 19, 2023

Prevalence and Preventability of Adverse Medicine Events in a Sample of Australian Aged-Care Residents: A Secondary Analysis of Data from the ReMInDAR TrialLisa M Kalisch Ellett, Gerel Dorj, Andre Q Andrade, et al.

Journal of Internal Medicine|June 7, 2023

Cardiovascular risk in rheumatoid arthritis patients treated with targeted synthetic and biological disease-modifying antirheumatic drugs: A multi-centre cohort studyXinning Tong, Chin-Yao Shen, Ha-Lim Jeon, et al.

The Lancet Regional Health. Western Pacific|July 5, 2022

Monoclonal antibodies and Fc-fusion protein biologic medicines: A multinational cross-sectional investigation of accessibility and affordability in Asia Pacific regions between 2010 and 2020Xinning Tong, Xue Li, Nicole L Pratt, et al.

Pharmacoepidemiology and Drug Safety|February 26, 2021

Suitability of databases in the Asia-Pacific for collaborative monitoring of vaccine safetyKatherine M Duszynski, James H Stark, Catherine Cohet, et al.

BMJ Open|April 25, 2020

Reducing medicine-induced deterioration and adverse reactions (ReMInDAR) trial: study protocol for a randomised controlled trial in residential aged-care facilities assessing frailty as the primary outcomeRenly Lim, Luke Bereznicki, Megan Corlis, et al.

Studies in Health Technology and Informatics|August 8, 2025

Predicting Infection Risk in Rheumatoid Arthritis Patients Treated with Biological and Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs: An Application of Machine LearningKuan Peng, Deliang Yang, Jiaqi Wang, et al.

Age and Ageing|April 23, 2022

Effect of an ongoing pharmacist service to reduce medicine-induced deterioration and adverse reactions in aged-care facilities (nursing homes): a multicentre, randomised controlled trial (the ReMInDAR trial)Elizabeth E Roughead, Nicole L Pratt, Gaynor Parfitt, et al.

Drug Safety|July 29, 2015

Variation in Association Between Thiazolidinediones and Heart Failure Across Ethnic Groups: Retrospective analysis of Large Healthcare Claims Databases in Six CountriesElizabeth E Roughead, Esther W Chan, Nam-Kyong Choi, et al.

Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|March 23, 2023

Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series AnalysisKuan Peng, Joseph E Blais, Nicole L Pratt, et al.

Pageof 11